485841-45-0Relevant articles and documents
Design and synthesis of orally bioavailable benzimidazoles as raf kinase inhibitors
Ramurthy, Savithri,Subramanian, Sharadha,Aikawa, Mina,Amiri, Payman,Costales, Abran,Dove, Jeff,Fong, Susan,Jansen, Johanna M.,Levine, Barry,Ma, Sylvia,McBride, Christopher M.,Michaelian, Jonah,Pick, Teresa,Poon, Daniel J.,Girish, Sandhya,Shafer, Cynthia M.,Stuart, Darrin,Sung, Leonard,Renhowe, Paul A.
supporting information; experimental part, p. 7049 - 7052 (2009/11/30)
A series of arylaminobenzimidazoles was designed and synthesized as Raf kinase inhibitors. Exploration of the structure-activity relationship resulted in compounds that are potent in vitro and show desirable in vivo properties.
BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
-
Page 342, (2008/06/13)
Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.